CR10927A - Composiciones y metodos de aplicacion topica y suministros transdermico de toxinas botulinum estabilizadas con fragmentos de polipeptido derivados de hiv-tat - Google Patents

Composiciones y metodos de aplicacion topica y suministros transdermico de toxinas botulinum estabilizadas con fragmentos de polipeptido derivados de hiv-tat

Info

Publication number
CR10927A
CR10927A CR10927A CR10927A CR10927A CR 10927 A CR10927 A CR 10927A CR 10927 A CR10927 A CR 10927A CR 10927 A CR10927 A CR 10927A CR 10927 A CR10927 A CR 10927A
Authority
CR
Costa Rica
Prior art keywords
hiv
tat
compositions
transdermic
supplies
Prior art date
Application number
CR10927A
Other languages
English (en)
Inventor
Jacob M Waugh
Jae Hoon Lee
Original Assignee
Revance Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Revance Therapeutics Inc filed Critical Revance Therapeutics Inc
Publication of CR10927A publication Critical patent/CR10927A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Cosmetics (AREA)

Abstract

Esta invencion se relaciona con composiciones novedosas de toxina botulinum que se estabilizan utilizando fragmentos HIV-TAT o derivados de fragmentos HIV-TAT. La composicion se puede administrar para varios propositos terapeuticos, esteticos y/o cosmeticos. La invencion tambien proporciona un metodo para estabilizar la toxina botulinum utilizando los fragmentos HIV-TAT o derivados de los fragmentos HIV-TAT.
CR10927A 2006-12-29 2009-07-14 Composiciones y metodos de aplicacion topica y suministros transdermico de toxinas botulinum estabilizadas con fragmentos de polipeptido derivados de hiv-tat CR10927A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US88263206P 2006-12-29 2006-12-29

Publications (1)

Publication Number Publication Date
CR10927A true CR10927A (es) 2009-09-14

Family

ID=39589170

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10927A CR10927A (es) 2006-12-29 2009-07-14 Composiciones y metodos de aplicacion topica y suministros transdermico de toxinas botulinum estabilizadas con fragmentos de polipeptido derivados de hiv-tat

Country Status (16)

Country Link
US (1) US20080233152A1 (es)
EP (1) EP2114426A4 (es)
JP (2) JP2010514781A (es)
KR (1) KR20090096735A (es)
CN (2) CN101616682A (es)
AR (1) AR064706A1 (es)
AU (1) AU2007340162B2 (es)
BR (1) BRPI0720730A2 (es)
CA (1) CA2677202A1 (es)
CO (1) CO6220834A2 (es)
CR (1) CR10927A (es)
MX (1) MX2009007068A (es)
NO (1) NO20092779L (es)
NZ (1) NZ598039A (es)
TW (1) TW200848072A (es)
WO (1) WO2008082889A2 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8092788B2 (en) 2004-03-03 2012-01-10 Revance Therapeutics, Inc. Compositions and methods for topical diagnostic and therapeutic transport
US9211248B2 (en) * 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
ZA200707352B (en) * 2005-03-03 2009-04-29 Revance Therapeutics Inc Compositions and methods for topical application and transdermal delivery of botulinum toxins
EP2178549B1 (en) 2007-07-26 2016-09-14 Revance Therapeutics, Inc. Antimicrobial peptide and compositions thereof
WO2009114748A1 (en) 2008-03-14 2009-09-17 Allergan, Inc. Immuno-based botulinum toxin serotype a activity assays
EP2334315B1 (en) * 2008-09-03 2023-01-18 NoNO Inc. Agents and methods for treatment of pain
WO2010078242A1 (en) * 2008-12-31 2010-07-08 Revance Therapeutics, Inc. Injectable botulinum toxin formulations
DK2413947T3 (da) * 2009-04-01 2020-06-02 Revance Therapeutics Inc Fremgangsmåder og sammensætninger til behandling af hudtilstande forbundet med vaskulær hyperreaktivitet
SG177357A1 (en) * 2009-06-25 2012-02-28 Revance Therapeutics Inc Albumin-free botulinum toxin formulations
WO2011023213A1 (en) * 2009-08-28 2011-03-03 Merz Pharma Gmbh & Co. Kgaa Modified chemodenervating agents
EP2305290A1 (en) * 2009-10-05 2011-04-06 Merz Pharma GmbH & Co. KGaA Salt-free composition comprising an intact Botulinum toxin complex
CA2774826A1 (en) * 2009-10-30 2011-05-05 Revance Therapeutics, Inc. Device and method for topical application of therapeutic or cosmetic compositions
WO2013068472A1 (en) * 2011-11-09 2013-05-16 Merz Pharma Gmbh & Co. Kgaa Modified neurotoxins with poly-glycine and uses thereof
KR20140139010A (ko) * 2012-03-22 2014-12-04 레반스 테라퓨틱스, 아이엔씨. 국소 화학탈신경제를 이용한 주름 치료 방법
US20140120077A1 (en) 2012-10-28 2014-05-01 Revance Therapeutics, Inc. Compositions and Methods for Safe Treatment of Rhinitis
CN103083651A (zh) * 2013-01-22 2013-05-08 南京中医药大学 用于外用制剂的穿膜肽介导的肉毒毒素的组合物及其制备方法和应用
EP2896864A1 (de) 2014-01-21 2015-07-22 Siemens Aktiengesellschaft Verbindungssystem
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
JP6821866B2 (ja) 2014-12-08 2021-01-27 ジェイワイエスケイ・スキン・ソリューションズ・プライベイト・リミテッドＪＹＳＫ Ｓｋｉｎ Ｓｏｌｕｔｉｏｎｓ Ｐｔｅ． Ｌｔｄ． 担体分子組成物および関連方法
KR102607534B1 (ko) * 2015-12-28 2023-11-29 오비다트 주식회사 TATdMt 펩타이드를 포함하는 미백 조성물
JP2025519507A (ja) 2022-06-10 2025-06-26 メディトックス インク． ボツリヌス毒素安定化組成物、それを含むボツリヌス毒素製剤及びそれに用いるためのポリペプチド

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US215412A (en) * 1879-05-13 Improvement in ironing-machines
US4078060A (en) * 1976-05-10 1978-03-07 Richardson-Merrell Inc. Method of inducing an estrogenic response
US4434228A (en) * 1982-04-20 1984-02-28 Genex Corporation Immobilization of biological materials in condensed polyalkyleneimine polymers
US4816568A (en) * 1986-05-16 1989-03-28 International Minerals & Chemical Corp. Stabilization of growth hormones
US5420105A (en) * 1988-09-23 1995-05-30 Gustavson; Linda M. Polymeric carriers for non-covalent drug conjugation
US5252713A (en) * 1988-09-23 1993-10-12 Neorx Corporation Polymeric carriers for non-covalent drug conjugation
US5744166A (en) * 1989-02-25 1998-04-28 Danbiosyst Uk Limited Drug delivery compositions
US6316003B1 (en) * 1989-12-21 2001-11-13 Whitehead Institute For Biomedical Research Tat-derived transport polypeptides
US5670617A (en) * 1989-12-21 1997-09-23 Biogen Inc Nucleic acid conjugates of tat-derived transport polypeptides
US5804604A (en) * 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
US5629020A (en) * 1994-04-22 1997-05-13 Emisphere Technologies, Inc. Modified amino acids for drug delivery
GB9120306D0 (en) * 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
US5607691A (en) * 1992-06-12 1997-03-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
US5709861A (en) * 1993-04-22 1998-01-20 Emisphere Technologies, Inc. Compositions for the delivery of antigens
US6974578B1 (en) * 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
US6986893B2 (en) * 1993-12-28 2006-01-17 Allergan, Inc. Method for treating a mucus secretion
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
NO180167C (no) * 1994-09-08 1997-02-26 Photocure As Fotokjemisk fremgangsmåte til å innföre molekyler i cellers cytosol
US5756468A (en) * 1994-10-13 1998-05-26 Wisconsin Alumni Research Foundation Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation
US5512547A (en) * 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
GB9600272D0 (en) * 1996-01-06 1996-03-06 Univ Nottingham Polymers
IL132941A0 (en) * 1997-05-21 2001-03-19 Univ Leland Stanford Junior Composition and method for enhancing transport across biological membranes
US5985434A (en) * 1997-11-25 1999-11-16 Kimberly-Clark Worldwide, Inc. Absorbent foam
AU751259B2 (en) * 1997-12-12 2002-08-08 Onyx Pharmaceuticals, Inc. Selective killing and diagnosis of p53+ neoplastic cells
WO1999042091A2 (en) * 1998-02-19 1999-08-26 Massachusetts Institute Of Technology Use of polycations as endosomolytic agents
US6261679B1 (en) * 1998-05-22 2001-07-17 Kimberly-Clark Worldwide, Inc. Fibrous absorbent material and methods of making the same
US6217912B1 (en) * 1998-07-13 2001-04-17 Expression Genetics, Inc. Polyester analogue of poly-L-lysine as a soluble, biodegradable gene delivery carrier
US6280937B1 (en) * 1998-08-14 2001-08-28 Rigel Pharmaceuticals, Inc. Shuttle vectors
US6958147B1 (en) * 1998-10-26 2005-10-25 Licentia Ltd Use of VEGF-C to prevent restenosis
ATE314859T1 (de) * 1998-10-27 2006-02-15 Mayo Foundation Botulinumtoxine zur verstärkung der wundheilung
US6627632B2 (en) * 1998-12-14 2003-09-30 Cellegy Pharmaceuticals, Inc. Compositions and methods for the treatment of anorectal disorders
US7056656B1 (en) * 1999-01-25 2006-06-06 University Of Medicine And Dentistry Of New Jersey Tat-derived oligourea and its method of production and use in high affinity and specific binding HIV-1 TAR RNA
US7008924B1 (en) * 1999-07-21 2006-03-07 Amgen, Inc. VGF fusion polypeptides
EP2269654A3 (en) * 1999-08-24 2011-04-13 Cellgate Inc. Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties
US6669951B2 (en) * 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
US7229961B2 (en) * 1999-08-24 2007-06-12 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into ocular tissues
US6730293B1 (en) * 1999-08-24 2004-05-04 Cellgate, Inc. Compositions and methods for treating inflammatory diseases of the skin
US20030104622A1 (en) * 1999-09-01 2003-06-05 Robbins Paul D. Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and viruses
US6544548B1 (en) * 1999-09-13 2003-04-08 Keraplast Technologies, Ltd. Keratin-based powders and hydrogel for pharmaceutical applications
US6458763B1 (en) * 1999-09-17 2002-10-01 Depuy Orthopeadics Bone sialoprotein-based compositions for enhancing connective tissue repair
US6610820B1 (en) * 1999-10-12 2003-08-26 University Of Lausanne Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US6844324B1 (en) * 1999-11-12 2005-01-18 Massachusetts Institute Of Technology Modular peptide mediated intracellular delivery system and uses therefore
US7070807B2 (en) * 1999-12-29 2006-07-04 Mixson A James Branched histidine copolymers and methods for using same
US20040109871A1 (en) * 2000-01-06 2004-06-10 Pascual David W. M cell directed vaccines
EP1586329A1 (en) * 2000-02-08 2005-10-19 Allergan, Inc. Botulinum toxin pharmaceutical compositions
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US20020009491A1 (en) * 2000-02-14 2002-01-24 Rothbard Jonathan B. Compositions and methods for enhancing drug delivery across biological membranes and tissues
US6670322B2 (en) * 2000-06-01 2003-12-30 Wisconsin Alumni Research Foundation Method of targeting pharmaceuticals to motor neurons
US20040033241A1 (en) * 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
US6306423B1 (en) * 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US20040220100A1 (en) * 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems
US20030215412A1 (en) * 2000-07-21 2003-11-20 Essentia Biosystems, Inc. Induction of hair growth with vascular endothelial growth factor
EP2364734B1 (en) * 2000-07-21 2017-09-06 ReVance Therapeutics, Inc. Multi-component biological transport systems
US20030219462A1 (en) * 2000-07-21 2003-11-27 Allergan Sales, Inc Clostridial neurotoxin compositions and modified clostridial neurotoxins
US6903187B1 (en) * 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
US6696038B1 (en) * 2000-09-14 2004-02-24 Expression Genetics, Inc. Cationic lipopolymer as biocompatible gene delivery agent
US20020127247A1 (en) * 2000-11-17 2002-09-12 Allergen Sales, Inc. Modified clostridial neurotoxins with altered biological persistence
US20020086036A1 (en) * 2000-12-05 2002-07-04 Allergan Sales, Inc. Methods for treating hyperhidrosis
US7255865B2 (en) * 2000-12-05 2007-08-14 Allergan, Inc. Methods of administering botulinum toxin
AU2002306500C1 (en) * 2001-02-16 2006-09-28 Cellgate, Inc. Transporters comprising spaced arginine moieties
CA2367636C (en) * 2001-04-12 2010-05-04 Lisa Mckerracher Fusion proteins
ES2312651T3 (es) * 2001-07-27 2009-03-01 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Toxina botulinum en el tratamiento o prevencion del acne.
BR0213989A (pt) * 2001-11-07 2005-03-01 Pharmacia Corp Métodos para promover a absorção e acúmulo nuclear de poliamidas em células eucarióticas
US7060498B1 (en) * 2001-11-28 2006-06-13 Genta Salus Llc Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers
EP1461084A2 (en) * 2001-12-11 2004-09-29 The Board Of Trustees Of The Leland Stanford Junior University Guanidinium transport reagents and conjugates
US20030113349A1 (en) * 2001-12-18 2003-06-19 Coleman William P. Topically applied clostridium botulinum toxin compositions and treatment methods
EP1487870A2 (en) * 2002-01-09 2004-12-22 Université de Lausanne Cell-permeable peptide inhibitors of the jnk signal transduction pathway
AU2003267943C1 (en) * 2002-02-26 2009-05-21 Altravax, Inc. Novel flavivirus antigens
US6688311B2 (en) * 2002-03-14 2004-02-10 Allergan, Inc. Method for determining effect of a clostridial toxin upon a muscle
US20030215395A1 (en) * 2002-05-14 2003-11-20 Lei Yu Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier
US7459164B2 (en) * 2002-05-28 2008-12-02 Botulinum Toxin Research Associates, Inc. Composition for therapeutic and cosmetic botulinum toxin
EP1531859A4 (en) * 2002-05-31 2005-12-07 Univ Jefferson COMPOSITIONS AND METHODS FOR TRANSEPITHELIAL MOLECULAR TRANSPORT
US7489812B2 (en) * 2002-06-07 2009-02-10 Dynamic Digital Depth Research Pty Ltd. Conversion and encoding techniques
US20040009180A1 (en) * 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
US7071167B2 (en) * 2002-11-13 2006-07-04 L'oreal Use of a combination of components with an inhibitory synergistic effect on calcium channels to prevent or treat wrinkles and fine lines
US6866856B2 (en) * 2002-12-31 2005-03-15 Avon Products, Inc. Compositions and delivery methods for the treatment of wrinkles, fine lines and hyperhidrosis
WO2004084905A2 (en) * 2003-03-24 2004-10-07 University Of Florida Use of 5-ht2c receptor activity affecting compounds for treating idiopathic hyperhidrosis and associated conditions
US8871224B2 (en) * 2003-12-09 2014-10-28 Allergan, Inc. Botulinum toxin therapy for skin disorders
KR101330775B1 (ko) * 2004-03-03 2013-11-18 레반스 테라퓨틱스, 아이엔씨. 보툴리눔 독소의 국소 적용 및 경피 전달을 위한 조성물 및 방법
US8092788B2 (en) * 2004-03-03 2012-01-10 Revance Therapeutics, Inc. Compositions and methods for topical diagnostic and therapeutic transport
US7691381B2 (en) * 2004-04-15 2010-04-06 Allergan, Inc. Stabilized biodegradable neurotoxin implants
US20060040882A1 (en) * 2004-05-04 2006-02-23 Lishan Chen Compostions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells
US7879341B2 (en) * 2004-07-26 2011-02-01 Merz Pharma Gmbh & Co. Kgaa Therapeutic composition with a botulinum neurotoxin
US20060024331A1 (en) * 2004-08-02 2006-02-02 Ester Fernandez-Salas Toxin compounds with enhanced membrane translocation characteristics
EP1661912A1 (en) * 2004-11-29 2006-05-31 Xigen S.A. Fusion protein comprising a BH3-domain of a BH3-only protein
WO2006094193A2 (en) * 2005-03-03 2006-09-08 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of an oligopeptide
ZA200707352B (en) * 2005-03-03 2009-04-29 Revance Therapeutics Inc Compositions and methods for topical application and transdermal delivery of botulinum toxins

Also Published As

Publication number Publication date
WO2008082889A3 (en) 2008-11-13
EP2114426A2 (en) 2009-11-11
JP2014001211A (ja) 2014-01-09
CN102988995A (zh) 2013-03-27
JP2010514781A (ja) 2010-05-06
NZ598039A (en) 2013-08-30
TW200848072A (en) 2008-12-16
AR064706A1 (es) 2009-04-22
WO2008082889A2 (en) 2008-07-10
US20080233152A1 (en) 2008-09-25
EP2114426A4 (en) 2010-07-21
BRPI0720730A2 (pt) 2014-04-08
NO20092779L (no) 2009-09-07
AU2007340162A1 (en) 2008-07-10
MX2009007068A (es) 2009-07-10
CA2677202A1 (en) 2008-07-10
CN101616682A (zh) 2009-12-30
KR20090096735A (ko) 2009-09-14
CO6220834A2 (es) 2010-11-19
AU2007340162B2 (en) 2013-08-01

Similar Documents

Publication Publication Date Title
CR10927A (es) Composiciones y metodos de aplicacion topica y suministros transdermico de toxinas botulinum estabilizadas con fragmentos de polipeptido derivados de hiv-tat
AU2018253620A1 (en) Injectable botulinum toxin formulations
MY169272A (en) Her2 antibody composition
MX2010008035A (es) Composicion que comprende anticuerpo que se fija al dominio ii de her2, y sus variantes acidas.
EA200802166A1 (ru) Стабильная фармацевтическая композиция с защитным действием от раздражения (варианты), способ ее получения и способ лечения кальций-миметиком с ее помощью
NO20090596L (no) Antivirale fosfinatforbindelser
BRPI0809164B8 (pt) Composição para administração tópica e composição farmacêutica compreendendo a referida composição
MY151036A (en) Synthesis of (r)-n-methylnaltrexone
BRPI0411316A (pt) uso de uma toxina clostrìdica para reduzir o apetite
EA200801531A1 (ru) Способы регулирования содержания маннозы в рекомбинантных белках
MX361727B (es) Variantes de polipeptido ph20, formulaciones y usos de las mismas.
BRPI0610108B8 (pt) compostos promotores de apoptose e composição que compreende os ditos compostos
UA103930C2 (ru) Соединения и композиция для лечения паразитарных болезней
BR112013001753A2 (pt) método para preparar uma composição d einter-alfa-inibidor (iaip) eriquecida de plasma, solução aquosa de iaip, e, método para tratar uma doença ou distúrbio associado com disfunção de iaip e associado com atividadede protease de serina no plasma aumentada.
EA201070689A1 (ru) Композиция для личного ухода
ATE442064T1 (de) Make-up-kit und -verfahren
ATE509931T1 (de) Azaadamantanester- und carbamatderivate sowie anwendungsverfahren dafür
MX2015012812A (es) Medicamentos novedosos que comprenden una composicion de anticuerpo enriquecida con isoforma de carga mayor.
BRPI0716754A8 (pt) Composição à base de xantoxilina e a respectiva utilização em cosmética
BRPI0609765A8 (pt) mistura de isoalcano, método para a preparação da mesma, composição cosmética ou farmacêutica, e, uso de uma mistura de isoalcano
NO20073762L (no) Visko-supplementsammensetning og fremgangsmater
DOP2007000073A (es) Compuestos para tratar la hipertensión pulmonar
BR112015030343A8 (pt) uso de um adjuvante de lipídeo de glicopiranosila (gla) e composição farmacêutica compreendendo o referido adjuvante
BRPI0815455C1 (pt) compostos derivados de n-fenilacetamida, composição farmacêutica, composição cosmética, uso cosmético de uma composição, e usos de um composto do mesmo
NO20072634L (no) Antiinfektive lipopeptider